On January 5, 2022, amendments came into force amending the Food and Drug Regulations to allow practitioners to request access to restricted drugs through the Special Access Program (SAP), which was previously prohibited. Restricted drugs are controlled substances that are listed in the Schedule to Part J of the Food and Drug Regulations which includes, for example, certain amphetamines and lysergic acid diethylamide (LSD). Health Canada revised its Special Access Program for drugs: Guidance document for industry and practitioners to reflect these amendments. The Guidance also addresses the need for an exemption under the Controlled Drugs and Substances Act, if a restricted drug is authorized for sale through the SAP.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
New guidance documents and regulatory amendments regarding therapeutic product shortages
As we have previously reported, in response to the COVID-19 pandemic, the Minister of Health had made interim orders pursuant to the Food and Drugs Act to address the significant risk to health posed ...Read More -
Competition Bureau resolves misleading performance claims case
On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made ...Read More -
Supreme Court of Canada denies leave to appeal refusal of NHP licence for BOLUOKE
On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the...Read More